See what questions
a doctor would ask.
Drug development company Endovasc Inc. reveals that initial results from Phase II Liprostatin trails are promising for Peripheral Vascular Disease sufferers. The drug acts as a vasodilator, platelet inhibitor and anti-inflammatory and anti-thrombotic agent and is therefore also useful for treatment of heart attacks, occlusive disease, ischemic ulcers, critical limb salvage and arthritis.
Source: summary of medical news story as reported by Business Wire
About: PVD sufferers show improvement after trialing new drug
Date: 9 June 2004
Source: Business Wire
More News Topics
Search Specialists by State and City